Zoetis Inc. $ZTS Shares Purchased by Swedbank AB

Swedbank AB raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 60.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,436,888 shares of the company’s stock after acquiring an additional 917,598 shares during the period. Swedbank AB owned approximately 0.55% of Zoetis worth $356,565,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis during the first quarter worth $25,000. 1248 Management LLC purchased a new position in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the 1st quarter worth $29,000. REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC increased its stake in shares of Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ZTS shares. JPMorgan Chase & Co. lowered their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. KeyCorp assumed coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Finally, Morgan Stanley set a $160.00 price target on shares of Zoetis in a research note on Thursday, December 18th. Six research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $160.18.

Zoetis Trading Down 0.3%

Shares of ZTS opened at $123.39 on Wednesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.40. The stock has a market cap of $54.38 billion, a price-to-earnings ratio of 20.77, a price-to-earnings-growth ratio of 2.69 and a beta of 0.97. The firm has a 50 day simple moving average of $128.09 and a 200-day simple moving average of $143.66.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. Zoetis’s quarterly revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is presently 33.67%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.